SEC Comment Letter 0000000000-24-007997 to DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc.
Date: July 15, 2024 · CIK: 0001401040 · Accession: 0000000000-24-007997
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280744
Letter
July 15, 2024 Rick Pauls Chief Executive Officer DiaMedica Therapeutics Inc. 301 Carlson Parkway, Suite 210 Minneapolis, MN 55305 Re:DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed July 10, 2024 File No. 333-280744 Dear Rick Pauls: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Amy E. Culbert, Esq.
Show Raw Text
July 15, 2024
Rick Pauls
Chief Executive Officer
DiaMedica Therapeutics Inc.
301 Carlson Parkway, Suite 210
Minneapolis, MN 55305
Re:DiaMedica Therapeutics Inc.
Registration Statement on Form S-3
Filed July 10, 2024
File No. 333-280744
Dear Rick Pauls:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Amy E. Culbert, Esq.